Biologics registers for immune-mediated inflammatory diseases: enhancing access to novel therapies and balancing drug safety concerns versus effectiveness

Impact: Health and wellbeing


Immune-mediated inflammatory diseases (IMIDs), affecting 3% of the UK population, are often life-ruining. New targeted biologic therapies are very expensive, and their safety and ‘real-world’ effectiveness were largely unknown at the point of drug approval. We led a series of national registry studies in rheumatoid arthritis (RA), psoriasis and systemic lupus erythematosus (SLE), representing ~50,000 patients, the largest such studies ever conducted worldwide. These translational pharmacoepidemiological investigations have greatly enhanced patients’ outcomes by influencing national and international treatment guidelines and have enhanced access for more than 1,000 people to these high-cost drugs through a unique National Institute for Health and Care Excellence (NICE) access scheme.

Category of impact

  • Health and wellbeing
1 Aug 2013 - 31 Jul 2020

Related information